Core Points - The implementation rules for the Nomination, Compensation, and Assessment Committee of the company aim to improve the governance structure and establish a sound system for the nomination, assessment, and compensation management of directors and senior management [1][2] - The committee is composed of independent and external directors, with independent directors holding a majority [2][3] - The committee's main responsibilities include researching selection criteria for directors and senior management, reviewing candidates, and proposing compensation policies [8][9][10] Group 1 - The committee is a specialized working body established by the board of directors and is accountable to the board [1] - The committee's term aligns with that of the board, and members can be re-elected [2] - The human resources department provides professional support and feedback on the implementation of the committee's decisions [2][3] Group 2 - The committee is responsible for proposing standards and procedures for selecting directors and senior management, as well as reviewing and recommending candidates [8][9] - The compensation and assessment committee specifically handles the formulation of assessment standards and compensation policies for directors and senior management [10][11] - The committee's proposals for director compensation must be approved by the board and submitted for shareholder review [11] Group 3 - The selection process for directors and senior management involves extensive communication and research on the company's needs [12] - The committee must conduct a thorough review of candidates' qualifications and obtain their consent before nomination [12][13] - The human resources department provides essential materials for the committee's reference, including financial and performance indicators [13][14] Group 4 - The evaluation process for directors and senior management includes self-assessment and performance evaluation based on established standards [15] - The committee meetings require a two-thirds attendance to be valid, and decisions should reflect independent opinions [15][16] - Meeting records must be kept, and confidentiality is required from all attendees [16][17]

证券代码：600180 证券简称：瑞茂通 公告编号：2025-047 债券代码：255290.SH 债券简称：24 瑞茂 01 债券代码：255553.SH 债券简称：24 瑞茂 02 瑞茂通供应链管理股份有限公司 关于第九届董事会第五次会议决议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 瑞茂通供应链管理股份有限公司（以下简称"公司"或"瑞茂通"）第九届 董事会第五次会议于 2025 年 8 月 29 日以现场加通讯方式召开。本次会议应出席 董事 6 人，实际出席会议董事 6 人。会议由公司董事长李群立先生主持，公司监 事、高级管理人员列席了会议。会议的召集和召开程序符合《中华人民共和国公 司法》和《公司章程》的规定，所形成的决议合法有效。 二、董事会会议审议情况 经与会董事审议和投票表决，会议决议如下： （一）审议通过《关于公司 2025 年半年度报告及摘要的议案》 公司 2025 年半年度报告及摘要准确、真实、完整反映了公司的财务状况和 经营成果。 表决结果：6 票同意，0 票反对，0 ...

证券代码：002989 证券简称：中天精装 公告编号：2025-068 债券代码：127055 债券简称：精装转债 深圳中天精装股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、会议召开情况 深圳中天精装股份有限公司（以下简称"公司"）第四届董事会第二十七次 会议于 2025 年 8 月 28 日在公司会议室以现场会议和通讯表决相结合的方式召开。 本次会议通知于 2025 年 8 月 18 日以电子邮件、通讯方式送达全体董事、监事、 高级管理人员。本次会议由董事长楼峻虎先生主持，应出席董事 9 名，实际出席 董事 9 名，其中董事伍安媛女士、郜树智先生、舒杰敏先生以远程通讯的方式出 席本次会议。全部监事及高级管理人员列席了本次会议。本次会议的召集、召开 符合有关法律法规、规范性文件及《公司章程》的规定。 二、会议审议情况 本次会议审议通过了如下议案，并形成如下决议： 与会董事认真审议了公司编制的《2025 年半年度报告》及其摘要，一致认 为报告内容真实、准确、完整地反映了公司 2025 年上半年的实际经营情况，不 存在任何虚假记载、误导性陈述 ...

General Overview - The document outlines the work guidelines for the Secretary of the Board of Directors of Ruimaotong Supply Chain Management Co., Ltd, aiming to enhance corporate governance and the role of the board secretary [1] Section 1: General Principles - The board secretary is a senior management position responsible for the company and the board, ensuring compliance with various laws and regulations [1] - The board secretary acts as the designated liaison between the company and the Shanghai Stock Exchange [1] Section 2: Qualifications and Appointment Procedures - The board secretary must possess necessary professional knowledge in finance, management, and law, along with good professional ethics [2] - Individuals with certain disqualifying conditions, such as recent administrative penalties from the China Securities Regulatory Commission, cannot serve as board secretary [2] - The company must appoint a new board secretary within three months of the previous secretary's departure [2][3] - During a vacancy, the board must appoint a temporary secretary and report this to the Shanghai Stock Exchange [2] Section 3: Responsibilities of the Board Secretary - The board secretary is responsible for managing information disclosure, coordinating communication with investors and regulatory bodies, and organizing board and shareholder meetings [3][4] - The secretary must ensure confidentiality of undisclosed significant information and report any leaks immediately [4] - The board secretary is tasked with training board members and senior management on compliance with relevant laws and regulations [4][5] Section 4: Support and Cooperation - The company must provide necessary support for the board secretary to perform their duties effectively, including access to financial and operational information [5] - In cases of obstruction, the board secretary has the right to report directly to the Shanghai Stock Exchange [5] Section 5: Miscellaneous - The guidelines become effective upon approval by the company's board and are subject to interpretation by the board [5]

债券代码：255553.SH 债券简称：24 瑞茂 02 瑞茂通供应链管理股份有限公司 关于第九届监事会第四次会议决议的公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 证券代码：600180 证券简称：瑞茂通 公告编号：2025-048 债券代码：255290.SH 债券简称：24 瑞茂 01 瑞茂通供应链管理股份有限公司（以下简称"公司"或"瑞茂通"）第九 届监事会第四次会议于 2025 年 8 月 29 日以现场加通讯方式召开。本次会议应 出席监事 3 人，实际出席监事 3 人。会议由公司监事会主席李金霞女士主持。 会议的召集和召开程序符合《中华人民共和国公司法》和《公司章程》的规定， 所形成的决议合法有效。 二、监事会会议审议情况 经与会监事审议和投票表决，会议决议如下： （一）审议通过《关于公司 2025 年半年度报告及摘要的议案》 监事会对公司 2025 年半年度报告及摘要进行了审核，提出如下审核意见： 《公司章程》和内部管理制度的各项规定； 券交易所的各项规定，所包含的信息能够从各方面 ...

Core Points - The second extraordinary general meeting of Guosen Securities Co., Ltd. was held on September 15, 2025, focusing on several important proposals including amendments to the company’s articles of association, personnel elections, and institutional adjustments [1] Group 1: Amendments and Major Acquisition Plans - Guosen Securities plans to comprehensively amend its articles of association and rename its shareholder meeting rules to align with new legal regulations and operational needs [2] - The company intends to acquire a total of 96.08% of Wanhe Securities Co., Ltd. by issuing A-shares at a price of 8.25 yuan per share, resulting in the issuance of 629,313,683 shares and a change in registered capital to 10,241,743,060 yuan [2] Group 2: Supervisory Board and Independent Director Election - The company plans to abolish its supervisory board and related systems in accordance with the Company Law and the revised guidelines from the China Securities Regulatory Commission [3] - Zhang Shouwen has been nominated as an independent director candidate, bringing extensive professional experience, including his current role as a professor at Peking University [3] Group 3: Institutional Revisions to Enhance Governance - Multiple company systems were revised, including those related to related party transactions, auditor selection, independent director work rules, and internal auditing, aimed at improving operational management and risk control [4] - The revisions are designed to comply with new legal requirements and enhance the company's governance structure, thereby increasing core competitiveness and sustainable development capabilities [4]

证券代码：600392 证券简称：盛和资源 公告编号：临2025-042 盛和资源控股股份有限公司 第九届董事会第四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、董事会会议召开情况 会办公室已依照公司章程的规定，以电子邮件或专人送达的方式通知了第九届董事会 所有董事。会议召集程序符合《公司法》和《公司章程》的有关规定。 实际参会董事 12 人。会议由公司董事长谢兵先生主持。公司部分高管人员列席本次 会议。 综上，本次会议的召开和表决程序符合《公司法》和《公司章程》的有关规定， 会议决议合法有效。会议以举手表决和通讯表决的方式审议通过如下议案。 二、董事会会议审议情况 （一）议案名称和表决情况 本报告已经董事会审计委员会事先认可并同意提交董事会审议。 本议案表决结果：同意 12 票，反对 0 票，弃权 0 票。 本议案表决结果：同意 12 票，反对 0 票，弃权 0 票。本议案需提交公司股东 会审议。 根据中国证监会《关于上市公司聘用、更换会计师事务所（审计事务所）有关问 题的通知》（ ...

Group 1 - The board meeting of Shandong Xinchao Energy Co., Ltd. was held on August 29, 2025, with all 8 directors present [1][2] - The board approved the revised 2024 annual work report, which will be submitted to the 2024 annual shareholders' meeting [2][3] - The board also approved the revised 2024 financial settlement report, which has been reviewed by the audit committee and will be submitted to the shareholders' meeting [2][3] Group 2 - A proposal to establish an internal control audit department was approved to enhance internal management and protect investors' rights [2][3] - The board approved the 2025 semi-annual report and its summary, confirming compliance with regulatory requirements [2][3] - A special report on the storage and actual use of raised funds for the first half of 2025 was also approved [3][4] Group 3 - The company plans to hold the 2024 annual shareholders' meeting on September 19, 2025, with all proposals receiving unanimous support [3][4]

Group 1 - The board of directors of Shenyuan Biopharmaceutical (Shanghai) Co., Ltd. held its fourth meeting on August 29, 2025, with all nine directors present, ensuring the legality and validity of the resolutions made [1][2] - The board approved the 2025 semi-annual report and its summary, confirming that the report accurately reflects the company's financial status and operational results for the first half of 2025, with no false records or misleading statements [1][2] - The board also approved the special report on the use of raised funds from January to June 2025, stating that the use of funds complies with relevant regulations and that all projects funded by the initial public offering have been completed [2][3] Group 2 - The board agreed to disclose the semi-annual evaluation report of the "Quality Improvement and Efficiency Enhancement Action Plan" for 2025, with unanimous approval from all directors [3] - The board proposed to cancel the supervisory board and amend the company's articles of association, which is aimed at improving the corporate governance structure and aligning with the latest legal requirements [4][5] - The board decided to convene the second extraordinary general meeting of shareholders for 2025 on September 25, 2024, to discuss the cancellation of the supervisory board and other operational regulations [5][6]

证券代码：688062 证券简称：迈威生物 公告编号：2025-043 表决结果：3 票同意，0 票反对，0 票弃权。 迈威（上海）生物科技股份有限公司 第二届监事会第十八次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 迈威（上海）生物科技股份有限公司（以下简称"公司"）第二届监事会 第十八次会议通知于 2025 年 8 月 19 日以书面方式送达全体监事，于 2025 年 8 月 29 日以现场结合通讯方式召开。会议由监事会主席楚键先生主持，会议应到 监事 3 人，实到监事 3 人。会议的召集、召开程序和方式符合《公司法》等法 律法规以及《迈威（上海）生物科技股份有限公司章程》（以下简称"公司章 程"）的有关规定，会议决议合法、有效。 二、监事会会议审议情况 （一）审议通过《关于公司<2025年半年度报告>及摘要的议案》 经审议，全体监事认为公司编制的《2025 年半年度报告》及摘要符合相关 法律法规、中国证监会及上海证券交易所的有关规定，并真实反映了公司 2025 年半年度的实际 ...